Table 7.
Liver and kidney functions of animals treated with AE or its LC dispersions
| Treatment (7.5 mg/kg per day) |
ALT (U/L) |
AST (U/L) |
Urea (mg/dL) |
Creatinine (mg/dL) |
|---|---|---|---|---|
| Negative control | 30.00±1.00 | 29.33±2.52 | 23.00±2.65 | 0.74±0.16 |
| Free AE | 29.00±1.00 | 25.50±3.08 | 26.55±2.77 | 0.90±0.13 |
| AE-LCNPs | 30.30±1.53 | 26.00±2.00 | 22.00±1.00 | 0.72±0.16 |
| AE-PEG-LCNPs | 28.33±1.53 | 29.00±4.60 | 22.37±0.87 | 0.82±0.11 |
Notes: The study was performed on Wistar rats model of six animals in each group (n=6). Values are expressed as mean ± SD. ALT: (F=1.272, P=0.347); AST: (F=1.155, P=0.3847); urea: (F=3.180, P=0.0848); creatinine: (F=1.012, P=0.4262). F, F-test (ANOVA) followed by post hoc test (Scheffe).
Abbreviations: AE, aloe-emodin; ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; LC, liquid crystalline; LCNPs, LC nanoparticles; PEG, polyethylene glycol; SD, standard deviation.